Organic Synthesis at the Service of Biology and Medicine

Ouathek Ouerfelli博士领导斯隆纪念馆的有机合成核心设施(OSCF) 凯特琳癌症中心(MSK)于2004年成立。他致力于为客户提供化学服务 MSK研究界和新工具和治疗剂的开发 癌症检测、预防和治疗。核心头拥有超过25年的 MSK研究人员的化学协作和服务，其中一半以上是NCI 受赠人。沿着这些思路，他为杰出的同事们的重大努力做出了贡献 NCI授权者，如Charles Sawyers博士(R01 CA155169)，导致FDA批准的药物， 斯科特·洛博士(R01 CA155169)与几个项目，显示出希望，以及博士。 克雷格·汤普森(RO1CA168802)致力于开发一种新的癌症标志物等。 他拥有最先进的设施，拥有化学合成方面的专业专业人员。 OSCF现在有能力支持药物化学努力，以进化出支持 MSK调查员。在他的领导下，该核心极大地促进了临床前研究 中心。

Dr. Ouathek Ouerfelli directs the organic synthesis core facility (OSCF) at Memorial Sloan Kettering Cancer Center (MSK) since 2004. He is committed to provide chemistry services for the MSK research community and the development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The core head possesses more than 25 years of chemistry collaborations and service of MSK investigators, more than half of whom are NCI grantees. Along these lines, he contributed to major endeavors by eminent colleagues who are NCI grantees such as Dr. Charles Sawyers (R01 CA155169) which led to an FDA approved drug, Dr. Scott Lowe (R01 CA155169) with several projects that are showing promise, as well as Dr. Craig Thompson (RO1 CA168802) for the development of a new cancer markers among others. He maintains a state-of-the art facility with expert professional personnel in chemical synthesis. OSCF has now the capability to support medicinal chemistry efforts to evolve agents in support of MSK investigators. Under his leadership, the core has greatly facilitated preclinical studies at the Center.